The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Estimated Market Size Of The G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market In 2026, And How Will Its Value Evolve By 2030?
The g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market has seen considerable expansion in recent years. Its value is expected to climb from $0.59 billion in 2025 to $0.78 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 32.7%. The observed growth during the historical period is attributable to several factors, such as progress in targeted cancer therapy research, the increasing incidence of multiple myeloma cases, the broadening of monoclonal antibody development initiatives, enhancements in clinical trial infrastructure, and growing investments in oncology drug discovery.
The g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market is projected to experience substantial expansion in the coming years. Its valuation is anticipated to reach $2.42 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 32.9%. This projected growth throughout the forecast period stems from factors such as a rise in regulatory clearances for targeted biological agents, escalating need for individualized cancer treatments, the broadening of next-generation immunotherapy platforms, increased financial commitments to precision medicine frameworks, and greater implementation of biomarker-guided therapy choices. Key developments expected during this period include the accelerated creation of bispecific antibody therapies, a sharpened emphasis on gprc5d biomarker-driven patient stratification, wider adoption of CAR-T cell systems, the enlargement of precision oncology clinical development programs, and improved integration of complementary diagnostic tools.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=33116&type=smp
Which Key Factors Are Driving The G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Growth?
An increasing incidence of myeloma is projected to fuel the expansion of the GPRC5D-targeted therapies market in the future. Myeloma, a malignancy affecting plasma cells within the bone marrow, interferes with typical blood cell formation and may lead to issues such as bone injury, reduced red blood cells, and renal dysfunction. The growing occurrence of myeloma is partially attributable to an aging demographic, given that the likelihood of developing plasma cell disorders escalates with advancing age due to the gradual buildup of genetic alterations. GPRC5D-targeted treatments aid in managing myeloma by attaching to the GPRC5D protein found on cancerous plasma cells, subsequently guiding the immune system, particularly T cells, to specifically eliminate these malignant cells, largely preserving healthy cells. As an illustration, in January 2026, the American Cancer Society, a professional organization located in the US, anticipates that in 2026, the United States will report approximately 36,000 new instances of multiple myeloma, with 20,150 cases among men and 15,850 cases among women, alongside an estimated 10,850 fatalities, consisting of 5,780 men and 5,070 women. Consequently, the increasing prevalence of myeloma is fueling the expansion of the GPRC5D-targeted therapies market.
How Is The G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Broken Down By Segment Categories?
The g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market covered in this report is segmented –
1) By Therapy Type: Monoclonal Antibodies; Bispecific Antibodies; Chimeric Antigen Receptor (CAR-T) Cell Therapies; Other Therapy Types
2) By Indication: Multiple Myeloma; Solid Tumors; Other Indications
3) By Technology: Precision Medicine Approaches; Molecular Targeted Therapy; Cancer Immunotherapy Platforms; Biopharmaceutical Drug Delivery Systems
4) By Route Of Administration: Intravenous; Subcutaneous; Other Routes Of Administration
5) By End-User: Hospitals; Specialty Clinics; Research Institutes; Other End-Users
Subsegments:
1) By Monoclonal Antibodies: Fully Human Monoclonal Antibodies; Humanized Monoclonal Antibodies; Chimeric Monoclonal Antibodies; Murine Monoclonal Antibodies
2) By Bispecific Antibodies: Dual Targeting Bispecific Antibodies; Cross Linking Bispecific Antibodies; Immune Cell Engaging Bispecific Antibodies; Cytotoxic Bispecific Antibodies
3) By Chimeric Antigen Receptor (CAR-T) Cell Therapies: Autologous Car T Cell Therapies; Allogeneic Car T Cell Therapies; Next Generation Car T Cell Therapies; Gene Edited Car T Cell Therapies
4) By Other Therapy Types: Targeted Small Molecule Drugs; Receptor Specific Inhibitors; Injectable Biologics; Oral Targeted Therapeutics
Which Trends Are Guiding The Direction Of The G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market?
Leading companies in the GPRC5D targeted therapies market are concentrating on developing innovative solutions, such as bispecific T cell engagers, to enhance immune-mediated targeting of cancer cells and improve treatment efficacy. A bispecific T-cell engager (BiTE) is an immunotherapy molecule designed to connect T-cells directly to cancer cells by simultaneously binding both, activating the T-cells to destroy the targeted cancer cells. For instance, in August 2023, Johnson & Johnson, a US-based healthcare company, received approval from the European Commission for TALVEY (talquetamab), Janssen’s bispecific antibody therapy targeting GPRC5D, for relapsed and refractory multiple myeloma (RRMM) in patients who have undergone at least three prior therapies. This is a first-in-class bispecific T-cell engager, targeting GPRC5D on multiple myeloma cells and CD3 on T cells, to treat relapsed/refractory multiple myeloma in heavily pretreated patients. Its key purpose is providing durable responses (ORR >70% in trials) after at least four prior therapies, with advantages including subcutaneous dosing, sustained quality-of-life benefits, and efficacy even post-bispecifics or CAR-T, thereby addressing an unmet need in late-line disease.
Which Players Are Present In The G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Space?
Major companies operating in the g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market are Johnson And Johnson, F. Hoffmann-La Roche AG., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Bristol Myers Squibb Company, Genmab A/S, Genentech Inc., Simcere Zaiming Biotechnology Co. Ltd., Innovent Biologics Inc., Essen Biotech Co. Ltd., Nanjing IASO Biotechnology Co. Ltd., CARsgen Therapeutics Holdings Limited, Oricell Therapeutics Co. Ltd., Integral Molecular Inc., Overland Therapeutics Inc., Qilu Pharmaceutical Co. Ltd., Leads Biolabs Ltd., ShanghAI Yake Biotechnology Co. Ltd., Guangzhou Bio-gene Technology Co. Ltd.
Get The Full G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Report:
Which Region Leads The G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market In Overall Market Size?
North America was the largest region in the GPRC5D targeted therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/customise?id=33116&type=smp
Browse Through More Reports Similar to the Global G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market 2026, By The Business Research Company
G Protein Coupled Receptors Market Report 2026
https://www.thebusinessresearchcompany.com/report/g-protein-coupled-receptors-global-market-report
Cc Chemokine Receptor Type 5 Market Report 2026
https://www.thebusinessresearchcompany.com/report/cc-chemokine-receptor-type-5-global-market-report
Gmp Cell Therapy Consumables Market Report 2026
https://www.thebusinessresearchcompany.com/report/gmp-cell-therapy-consumables-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model